BTIG Maintains LENSAR(LNSR.US) With Hold Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Lucid Diagnostics (LUCD), LENSAR (LNSR) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
BTIG Downgrades LENSAR(LNSR.US) to Hold Rating
Lake Street Downgrades LENSAR(LNSR.US) to Hold Rating, Raises Target Price to $15
LENSAR Analyst Ratings
Lake Street Downgrades LENSAR to Hold From Buy, Price Target Is $15
Lake Street Reaffirms Their Buy Rating on LENSAR (LNSR)
BTIG Maintains LENSAR(LNSR.US) With Buy Rating, Maintains Target Price $15
Lensar Is Maintained at Buy by Lake Street
LENSAR Analyst Ratings
Lake Street Maintains Buy on LENSAR, Raises Price Target to $16
BTIG Maintains LENSAR(LNSR.US) With Buy Rating, Raises Target Price to $15
Analysts' Top Healthcare Picks: Compass Therapeutics (CMPX), LENSAR (LNSR)
Lake Street Maintains LENSAR(LNSR.US) With Buy Rating, Maintains Target Price $12
Lake Street Maintains LENSAR(LNSR.US) With Buy Rating, Maintains Target Price $12
Lake Street Maintains LENSAR(LNSR.US) With Buy Rating, Raises Target Price to $12
BTIG Maintains LENSAR(LNSR.US) With Buy Rating, Raises Target Price to $10
Lake Street Maintains LENSAR(LNSR.US) With Buy Rating, Maintains Target Price $8
Lake Street Maintains LENSAR(LNSR.US) With Buy Rating, Maintains Target Price $8
Lake Street Maintains LENSAR(LNSR.US) With Buy Rating, Maintains Target Price $8